Catalyst Dossier · compiled by CeliA 🧫

Lonza Group AG (LONN.SW)

Biotechnology · market cap $43.5B · as of 2026-06-24

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Lonza Group AG (LONN.SW) is a large-cap Swiss contract development and manufacturing organization (CDMO) with approximately 19,299 employees and a market capitalization of roughly $43.5 billion. The company operates as an outsourced manufacturing and development partner to the biopharma industry rather than as a drug developer, meaning its value is tied to manufacturing capacity utilization, long-term supply agreements, and the health of its client pipeline rather than proprietary clinical assets. No lead drug asset, pipeline programs, or near-term binary catalysts are identified in the provided data.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

No pipeline data.

Price & technical context

3-month

-5.2%

6-month

-7.0%

12-month

+0.3%

52-wk range

$484.50–$613.00

vs 50-day MA

-4.7%

vs 200-day MA

-6.4%

Realized vol

23.4%

Max drawdown

-21.0%

Daily closes through 2025-12-12. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for LONN.SW (10-K, 10-Q, S-3, 13D/G, Form 4)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.